A budget impact analysis of gilteritinib for the treatment of relapsed or refractory FLT3mut+ acute myeloid leukemia in a US health plan
Author:
Affiliation:
1. Astellas Pharma Global Development, Inc, Northbrook, IL, USA
2. Analysis Group, Inc, Boston, MA, USA
Publisher
Informa UK Limited
Subject
Health Policy
Link
https://www.tandfonline.com/doi/pdf/10.1080/13696998.2020.1851698
Reference64 articles.
1. Acute Myeloid Leukemia
2. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007
3. Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
4. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
5. FLT3: ITDoes matter in leukemia
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A real-world, retrospective, observational study examining treatment patterns and clinical outcomes in patients with FLT3m + AML in Japan;Current Medical Research and Opinion;2023-11-02
2. Scenario Analysis When Conducting Budget Impact Analyses for Rare Diseases;The American Journal of Managed Care;2022-10-05
3. Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy;Expert Opinion on Pharmacotherapy;2021-12-14
4. When it comes to drug access, should children be considered small adults? Countering coverage denials of FLT3 inhibitors in children with FLT3‐ITD AML;Pediatric Blood & Cancer;2021-08-06
5. Budget impact analysis: can we afford the added value?;Journal of Medical Economics;2021-01-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3